Is Thymosin Alpha-1 Legal in Washington State?
At a glance
- FDA approval / None in the United States [1]
- FDA advisory committee vote / 4 yes, 17 no, December 2024 [2]
- FDA list for state-licensed pharmacies / In none of the three categories [3]
- FDA list for outsourcing facilities / Category 3, nominated without adequate support [4]
- HHS October 2026 peptide draft / Not one of the six peptides covered [5]
- Approved outside the US / Italy, India, Hong Kong [1]
- WADA Prohibited List / Not named [6]
What the FDA records show about compounding
Thymosin alpha-1, also called thymalfasin or Ta1, is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5; thymalfasin is the synthetic version with the same sequence [1]. It has no US approval [1]. For an unapproved peptide, the practical question is whether a licensed pharmacy may compound it. FDA's records on that point do not show an allowance for this peptide.
On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both thymosin alpha-1 free base and the acetate [2]. Members who voted no cited no compelling evidence of clinical effectiveness and safety; some who voted yes said patients should have access [2]. FDA proposed that the peptide not be added to the list of bulk substances state-licensed pharmacies may use in compounding [2].
FDA's page on bulk substances that may raise significant safety risks, content dated April 22, 2026, lists thymosin alpha-1 in its nominated-but-withdrawn table: it had been in the significant-risk category and came off when the nominators withdrew. FDA's stated concerns remain: significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information FDA called inadequate to understand the extent of any safety issues [7].
On FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, thymosin alpha-1 appears in none of the three categories [3]. On the list for outsourcing facilities, updated March 21, 2025, it sits in category 3, nominated without adequate support, and FDA's category 1 policy of generally taking no action against compounders does not apply to it [4]. The October 2026 HHS draft proposes enforcement discretion for six peptides, and thymosin alpha-1 is not among them [5].
What this means in Washington
No Washington rule specifically banning or permitting thymosin alpha-1 was found, so the federal points above are the documented ones: the peptide is unapproved [1], and FDA proposed against adding it to the pharmacy bulks list [2]. Nothing found shows that a particular product or use of it is legal in Washington.
WADA Prohibited List
Thymosin alpha-1 is not named on WADA's 2026 Prohibited List [6]. WADA does name thymosin-beta-4 and its derivatives such as TB-500 under S2.3, a different peptide [6].
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
Can a US pharmacy compound thymosin alpha-1?
Is thymosin alpha-1 covered by the October 2026 HHS peptide policy?
Is thymosin alpha-1 named on the WADA Prohibited List?
References